Eligible patients diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC) meeting all inclusion and exclusion criteria will be approached for participation. Prior to enrollment, all participants will be thoroughly informed about the study objectives, procedures, potential risks and benefits using patient information sheet. Written informed consent will be obtained from each patient before any study-related procedures are initiated. A total of 50 patients with histologically confirmed metastatic hormone-sensitive prostate cancer (mHSPC) will be enrolled in the study. Patients will be randomly assigned in a 1:1 ratio to two treatment arms: Group A: ADT + Abiraterone (1000 mg/day) + Prednisolone (5 mg twice daily), Group B: ADT + Abiraterone (1000 mg/day) + Prednisolone (5 mg twice daily) + Docetaxel (75 mg/m² IV for 6 cycles). The process of randomization will begin once histopathology report of the primary TRUS guided biopsy is obtained. Randomization will be done using a computer-generated randomization schedule using block randomization technique. Sequentially numbered, opaque, sealed envelopes (SNOSE) will be used for allocation concealment. Both the treating surgeon and the patients will be aware of the management proposed. Patients will be block-randomized in a 1:1 ratio into two treatment arms: Group A: ADT + Abiraterone and Group B: ADT + Abiraterone + Docetaxel. Patients will be followed at regular intervals every 12 weeks for clinical assessment and laboratory monitoring, including PSA levels and adverse events. PSMA PET-CT will be repeated at 6 months and 12 months or earlier if biochemical or clinical progression is suspected. Patients will be followed for a minimum of 12 months or until disease progression, death, or withdrawal from the study. Systematic collection of data will be done using data collection sheet at baseline and at scheduled follow-up visits. This will include demographic details, clinical history and physical examination findings, laboratory values, imaging findings (including PSMA PET CT scans), treatment details, adverse events, PSA levels and progression, radiological assessments. All data will be anonymized and stored securely for analysis. After obtaining written informed consent, participants will undergo a series of basic investigations in accordance with institutional guidelines which are part of routine clinical practice. This will include complete blood count (CBC), renal function tests (serum creatinine and calculated creatinine clearance), liver function tests (bilirubin, AST, ALT, ALP), serum potassium levels, PSA levels, ECG and echocardiography for cardiac function (including ejection fraction), PSMA PET CT for staging and metastasis documentation, Ophthalmologic evaluation in patients with impaired vision.